In the original article, there was an error in the CpG oligo-dinucleotide sequence used as adjuvant.

A correction has been made to the section "Materials and Methods", paragraph "Antibodies and adjuvants": CpG oligo-dinucleotides 5′-ggTGCATCGATTTATCGATTATCGATGCAGggggg-3′ with lower case letters for phosphorothioate linkages and upper case letters for phosphodiester linkages previously shown to be efficient in pigs (26) were bought from Sigma.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
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